TheFlyOnTheWall.com reported this morning that Gilead Sciences, Inc. (NASDAQ:GILD), announced that the company has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, which is a  nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection. Gilead Sciences, Inc.(NASDAQ:GILD) opened trading today at $82.18 and…